Find comprehensive information on Jardiance (empagliflozin) for healthcare professionals. Learn about Jardiance ICD-10 codes, medical billing guidelines, clinical documentation improvement tips, and best practices for coding diabetes mellitus type 2, heart failure, and chronic kidney disease. Explore resources for accurate Jardiance coding, compliant documentation, and improved patient care. This resource provides essential insights for physicians, coders, and clinical documentation specialists navigating Jardiance usage and documentation within medical records.
Also known as
Type 2 diabetes mellitus
Jardiance is used to treat type 2 diabetes.
Heart failure
Jardiance is also used to reduce the risk of cardiovascular death in heart failure patients.
Long term (current) use of insulin
Jardiance may be used in conjunction with insulin in some patients.
Long term (current) use of oral hypoglycemic drugs
Jardiance is an oral hypoglycemic medication.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Jardiance prescribed for type 2 diabetes mellitus?
When to use each related code
| Description |
|---|
| Type 2 diabetes mellitus |
| Heart failure with reduced EF |
| Chronic kidney disease |
Coding Jardiance without documented, confirmed type 2 diabetes diagnosis leads to inaccurate claims and potential denial. Proper CDI crucial.
Coding Jardiance for unapproved indications lacks medical necessity justification. Audit risk high. Clear documentation vital for compliance.
Jardiance use for CKD requires specific diagnosis and staging documentation. Insufficient documentation creates coding and billing errors.
Patient presents for management of type 2 diabetes mellitus. The patient reports adherence to current diet and exercise regimen. Current medications include metformin 1000mg twice daily and glipizide 10mg daily. HbA1c at last visit was 8.2%. Discussion regarding optimizing glycemic control included the benefits and risks of adding a sodium-glucose co-transporter-2 (SGLT2) inhibitor. After a thorough review of the patient's medical history, including renal function with an eGFR of 75 mLmin1.73 m2, cardiovascular risk factors, and current medication list, Jardiance (empagliflozin) was prescribed at an initial dose of 10mg daily. Patient education was provided regarding potential side effects such as genital mycotic infections, urinary tract infections, and the importance of monitoring for signs of volume depletion. The patient was also counseled on the cardiovascular and renal benefits associated with SGLT2 inhibitor use. Emphasis was placed on regular blood glucose monitoring and follow-up appointment scheduled in four weeks to assess treatment efficacy and tolerability. ICD-10-CM code E11.9, type 2 diabetes mellitus without complications, was documented. Emphasis on medication adherence and lifestyle modifications were reinforced.